Gain Therapeutics, Inc.

NASDAQ:GANX

Biotechnology

Healthcare
$1.18 +3.09%

+$0.06 today

Market cap
$50.33M
Beta
0.16
P/E (TTM)
-3.6
EPS (TTM)
-$0.50
52W Low $1.41High $4.34

Volume 4.26M

Average 0.64M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$18.47M

FY 2025 · Annual

Investing Cash Flow

$0.00

FY 2025 · Annual

Financing Cash Flow

$28.45M

FY 2025 · Annual

+118.6% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(13.89M)(17.59M)(22.27M)(20.41M)(20.16M)
Depreciation & Amortization15.48K64.17K83.58K84.07K94.05K
Deferred Income Tax00000
Stock-Based Compensation839.37K1.53M3.26M2.39M1.8M
Change in Working Capital(329.78K)1.51M442.23K(1.08M)(1.01M)
Accounts Receivables(63.35K)3.63K000
Inventory00000
Accounts Payables(521.39K)1.07M(643.16K)274.89K(468.61K)
Other Working Capital254.96K444.52K1.09M(1.36M)(537.91K)
Other Non-Cash Items999.87K(206.86K)(383.19K)143.52K804.94K
Operating Cash Flow(12.37M)(14.69M)(18.87M)(18.87M)(18.47M)
Capital Expenditures(94.21K)(118.95K)(15.36K)(22.49K)0
Acquisitions (Net)00000
Purchases of Investments0(17.74M)(1.96M)00
Sales of Investments03.08M12.19M5M0
Other Investing Activities00000
Investing Cash Flow(94.21K)(14.77M)10.22M4.98M0
Debt Repayment(21.95K)(78.77K)(89.07K)(90.88K)(96.5K)
Common Stock Issued42.63M012.73M13.21M28.54M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(841.27K)00(109.36K)0
Financing Cash Flow41.77M(78.77K)12.64M13.01M28.45M
Effect of Forex Changes100.78K(23.8K)488.4K(527.17K)469.43K
Net Change in Cash29.41M(29.57M)4.49M(1.41M)10.46M
Free Cash Flow(12.46M)(14.81M)(18.88M)(18.9M)(18.47M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$20.2M
+ D&A$94.0K
+ Stock-Based Comp$1.8M
+ Deferred Tax$0
- Working Capital-$1.0M
+ Other Non-Cash$804.9K
= Operating Cash Flow-$18.5M
- Capex$0
= Free Cash Flow-$18.5M

Analysis

FY2025 free cash flow is -$18.5M. FCF conversion is 91.6% of net income. Operating cash flow was -$18.5M, with capex of $0. The largest bridge item is Stock-Based Comp at $1.8M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 17, 2026
8-KCurrent reportNov 10, 2026
10-QQuarterly reportNov 10, 2026
4Statement of changes in beneficial ownershipOct 30, 2026
3Initial statement of beneficial ownershipOct 30, 2026

Does GANX generate free cash flow?

Gain Therapeutics, Inc. (GANX) generated -$18.47M of free cash flow in fiscal 2025.

How much operating cash flow does GANX produce?

Operating cash flow was -$18.47M, before capital expenditures of $0.00.